On November 16, Summit Therapeutics PLC fell 11.52% in Regular Trading, trading at $12.57 per share with turnover of $56.47 million.
The move followed the company’s disclosure that the FDA issued a complete response letter for the biologics license application covering ivonescimab in previously treated advanced lung cancer, meaning the application was not approved.
According to the company update, the FDA said that without evidence of an overall survival improvement, progression-free survival benefit alone was insufficient to support a favorable benefit-risk profile. Summit Therapeutics PLC did not provide a timeline for resubmission or specify what additional evidence it may submit, adding pressure to commercialization expectations. Earlier reports also noted the setback came despite acceptable safety and prior clinical focus on ivonescimab, amplifying investor concern.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments